Neonatal sepsis, a systemic infection in the first 28 days of life, encompasses bloodstream infections, meningitis, and pneumonia. It is the third most common cause of deaths among neonates, accounting for 225 000 deaths globally every year.[@ref1]

South Asia and sub-Saharan Africa have the highest burden of neonatal sepsis in the world. Of the total sepsis related neonatal deaths in 2013, 38.9% occurred in South Asia.[@ref1] [@ref2] Poverty, low coverage of effective interventions, including facility births, and gross inequities in delivery of healthcare[@ref3] contribute to this situation. We review the available literature ([box 1](#box1){ref-type="boxed-text"}) to draw attention to the burden of neonatal sepsis, the pathogen profile, and the extent of antimicrobial resistance in South Asia, and propose priority actions for policymakers and health professionals in the region.

###### Sources and methods

We searched PubMed and Web of Science for literature published between January 2000 and August 2018 using the search terms: (newborn OR neonate) AND (sepsis OR infection OR antibiotic OR antimicrobial). The results were filtered for South Asian countries. Bibliographies of full text articles and published systematic reviews were also searched to identify additional articles.

We identified 2699 and 220 articles from PubMed and Web of Science, respectively, and 19 additional articles from reference lists of identified articles. After removing duplicates, we screened 2768 articles and reviewed 223 full text articles. Finally, 109 studies were included: 69 from India, 16 from Pakistan, 7 from Bangladesh, 14 from Nepal, 1 from Sri Lanka, and 2 multi-country studies (Young Infant Study[@ref4] and Aetiology of Neonatal Infections in South Asia (ANISA)[@ref5]) covering Bangladesh, India, and Pakistan). Because the datasets belonging to different time periods and/or different patient populations in a given study were considered unique, we had a total of 123 datasets from 109 studies.

Two authors (SS and SC) extracted information from the relevant studies. Most studies were hospital based, single centre studies that reported data on neonates with suspected sepsis or laboratory based studies reporting bacteriological profile and antimicrobial resistance of cultures received from neonatal intensive care units. We identified only eight relevant community based studies. Random effects meta-analysis was done to pool the results, if applicable, using the "metan" command in Stata 15.1 (StataCorp, College Station, TX). Pooling of rates was done separately for the hospital based and community based studies. See appendix on bmj.com for details of the methods and studies included.

Paucity of high quality data
============================

We found no data on neonatal sepsis from Afghanistan, Bhutan, Maldives, and little from Sri Lanka. While the neonatal health indicators of three of these four countries are reasonably good,[@ref3] the paucity of data from war torn Afghanistan is a cause for concern.

More importantly, the data from the four countries with the highest burden of neonatal sepsis (India, Pakistan, Nepal, and Bangladesh) are of poor quality. With the exception of studies such as the Young Infant Study,[@ref4] ANISA,[@ref5] and the multisite study from the Delhi Neonatal Infections Study[@ref7] collaboration, most studies are retrospective, lack rigorous methods and standard definitions, and have used passive surveillance to identify cases. There is therefore an inherent risk of underestimating the burden of sepsis in the region.

High incidence of sepsis
========================

The pooled incidence of culture positive sepsis in hospital based reports from South Asia is 15.8 per 1000 live births (95% CI 12.7 to 18.8, n=15 reports). This is about twofold to fourfold higher than that reported in high income countries such as England and the United States.[@ref8] [@ref9] The incidence does not seem to have declined in the last decade.[@ref10] About a third of neonates with culture positive sepsis died as a result (median case fatality rate 34.4%). [Table 1](#tbl1){ref-type="table"} presents incidence and case fatality rates by country.

###### 

Incidence, case fatality rates, and infecting organism for neonatal sepsis in hospital based studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          India                       Pakistan                   Bangladesh                 Nepal                      Sri Lanka                     Total
  ----------------------------------------------------------------------- --------------------------- -------------------------- -------------------------- -------------------------- ----------------------------- ---------------------------
  No of studies (No of isolates)                                          64 (18 761)                 16 (3557)                  6 (584)                    14 (1325)                  1 (9)                         101\* (24 244)

  Incidence (95% CI) of culture positive sepsis, per 1000 live births;\   16 (12.8 to 19.2); n=14     NA                         NA                         11.6 (18.4 to 14.7); n=1   13.6/1000 patient days; n=1   15.7 (12.7 to 18.8); n=15
  No of studies                                                                                                                                                                                                      

  Case fatality rate (95% CI); No of studies                              34.4 (33 to 35.7); n=14     30.9 (25.7 to 36.2); n=2   19.1 (11.7 to 26.5); n=2   64.7 (54.3 to 75); n=1     NA                            34.4(33.1 to 35.6); n=19

  \% Infecting organism (95% CI); No of studies                                                                                                                                                                      

  *Klebsiella* spp†                                                       53.6 (50.7 to 56.5); n=21   NA                         NA                         33 (3.0 to 63.0); n=1      60                            53.3 (50.4-56.2); n=22

  *Escherichia coli*†                                                     42.2 (38.5 to 46); n=16     NA                         NA                         50 (1.0 to 98.0); n=1      NA                            42.2 (38.6 to 46.2); n=17

  Meticillin resistant *Staphylococcus aureus*                            43.2 (39.9 to 46.5); n=17   61 (49.1-72.8); n=1        NA                         26 (12.8 to 39.3); n=3     NA                            46.5 (41.9 to 51.1) n=21
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data represent pooled proportions (95% CI), unless stated otherwise. NA= not available

Community based studies (n=8) are not included in table.

Extended spectrum β lactamase.

Sepsis is categorised into early onset sepsis (onset within 72 hours of birth) and late onset sepsis (beyond 72 hours). Early onset sepsis is thought to be caused by pathogens vertically transmitted from mothers while late onset sepsis is attributed to pathogens acquired horizontally from the environment or care givers, or both. About 62% of the infections in South Asia occur in the first 72 hours of life, roughly translating into an incidence of 9.8 per 1000 live births. This is 10-fold higher than the incidence of early onset sepsis reported in a large nationwide study in the United States.[@ref9]

Neonatal sepsis is classified as culture positive or culture negative, depending on isolation of pathogen(s) from blood or other sterile fluids. Based on the available data, this review focuses on the burden of culture positive sepsis, which forms only part of the total number of sepsis cases. Because of the difficulty in obtaining an adequate volume of blood in preterm neonates and the low levels of bacteraemia, blood cultures tend to be sterile in many neonates. The culture positive versus culture negative sepsis ratio ranges from 1:6 to 1:16 in high income countries.[@ref11] The ratio is likely to be more skewed towards culture negative sepsis in South Asia, given the poor microbiological laboratory support in most units. The burden of total neonatal sepsis is therefore likely to be much higher.

The proportion of neonates with culture positive sepsis in community based studies was lower---12.3 per 1000 live births (95% CI 8.4 to 16.2). However, this was influenced by the ANISA study,[@ref5] which used a statistical model incorporating the results of molecular assays to estimate the incidence of bacterial sepsis. If only conventional blood culture positive results are included, the pooled risk of sepsis was much lower---5.5 per 1000 live births (95% CI 2.4 to 8.6).

Unique pathogen profile
=======================

The pathogen profile in South Asia is different from that found in high income countries. There is a predominance of Gram negative pathogens (\>60%) and a low prevalence of group B streptococci in South Asia, compared with a high incidence of group B streptococci in high income countries.[@ref7] [@ref10]

Among isolates from hospital settings (n=24 273), Gram negative organisms (63%) were the most common, with *Klebsiella* spp (23%), *Escherichia coli* (14%), and *Acinetobacter* spp (8%) being the top three. The most common Gram positive organisms were *Staphylococcus aureus* (20%) and *Coagulase negative Staphylococci* (9%). Gram negative organisms were associated with higher case fatality (pooled proportion 26.7%; 95% CI 0 to 41%) than Gram positive organisms (11.9%; 95% CI 10.5 to 13.3%). Among the 703 isolates from community settings, *Klebsiella spp* (25%), *E coli* (15%), and *S aureus* (12%) were the most common.

The predominance of Gram negative pathogens in South Asia suggests that the transition from Gram negative pathogens to Gram positive organisms such as group B streptococci that happened five to six decades ago in developed countries[@ref10]---largely because of improved aseptic routines, including hand hygiene in neonatal intensive care units---is yet to take place in South Asia.

There was a striking similarity between the pathogen profile of early onset and late onset sepsis (see supplementary fig 2 on bmj.com). This challenges the assumption of attributing early onset sepsis to vertical transmission from the mothers. Although it is possible that the pregnant women in South Asia are colonised with pathogens normally found in the hospitals (such as *Klebsiella*), it is more probable that the source of infection in early onset sepsis is the unhygienic practices in the labour rooms and neonatal intensive care units. Identifying the source and transmission pathways of common pathogens of early onset sepsis is essential to determine the appropriate steps to prevent infection that will help to reduce the high burden of mortality associated with early onset sepsis in the region.

Spiralling antimicrobial resistance
===================================

Antimicrobial resistance has worsened in the last decade, rendering most antibiotics obsolete. Resistance to even "reserve" antibiotics has increased---50-70% of the common Gram negative isolates are now multidrug resistant. [Table 2](#tbl2){ref-type="table"} presents antimicrobial resistance patterns found in common pathogens in hospital and community settings in South Asia.

###### 

Pathogen specific antimicrobial resistance in isolates from babies with neonatal sepsis in South Asia

                                 \% of isolates resistant (95% CI); No of isolates                                                                                                                  
  ------------------------------ --------------------------------------------------- --------------------------- --------------------------- --------------------------- -------------------------- ---------------------
  Hospital settings                                                                                                                                                                                 
  *Klebsiella* spp (n=4312)      86.8 (85.8 to 87.3); 2806                           75.3 (74 to 76.7); 2954     72.5 (71.3 to 73.7); 4126   74.5 (73 to 75.9); 2455     10.4 (9.4 to 11.5); 2540   70.7 (66.1 to 75.3)
  *E coli* (n=2798)              88.2 (87 to 89.5); 2196                             67.9 (66 to 69.8); 2254     66.9 (65.3 to 68.6); 2745   69.4 (67.4 to 71.4); 1773   8.1 (6.8 to 9.4); 1551     54.0 (48.1 to 59.9)
  *Acinetobacter* spp (n=1347)   86.2 (83.8 to 88.5); 633                            68.1 (65.1 to 71); 792      80.3 (78.2 to 82.4); 1121   73.6 (70.8 to 76.3); 718    64.8 (62.2 to 67.4); 828   78.7 (73.9 to 83.4)
  *S aureus* (n=2437)            69 (67.3 to 70.6); 2266                             54.5 (52.4 to 56.6); 1773   51.2 (49 to 53.3);1753      NA                          46.5 (41.9 to 51.1); 310   NA
  Community settings                                                                                                                                                                                
  *Klebsiella* spp (n=116)       87.9 (82.3 to 93.5)                                 22.8 (15 to 30.1)           25.7 (18 to 33.5)           28.5 (19.8 to 37.1)         0 (0 to 2)                 ---
  *E coli* (n=37)                72.4 (58 to 86)                                     18.7 (6 to 31)              50.3 (35 to 65.7)           37 (13.3 to 60.6)           0 (0 to 2)                 ---
  *S aureus* (n=77)              74.6 (66.6 to 82.6)                                 3 (0-9)                     9 (2 to 16)                 NA                          10 (0 to 20.5)             ---

Data represent pooled proportion (95% CI); n=number of isolates tested, unless stated otherwise.

NA=not applicable.

The common pathogens from hospital based studies uniformly exhibit a high degree of resistance to first line drugs recommended by the World Health Organization---namely, ampicillin, gentamicin, and third generation cephalosporins such as cefotaxime ([table 2](#tbl2){ref-type="table"}).[@ref6] However, most were susceptible to WHO classified "watch group"[@ref6] antibiotics, such as meropenem (see suppl table 1 on bmj.com). About half (pooled proportion 46.5%; 95% CI 41.9 to 51.1) of *S aureus* isolates were meticillin resistant, but most remained susceptible to watch group antibiotics such as vancomycin. The varied pathogens with high resistance patterns preclude the use of intrapartum antibiotic prophylaxis to prevent vertically transmitted infection. In contrast, the antimicrobial resistance profile in the community based studies was not so high: although resistance to ampicillin was high, resistance to gentamicin and third generation cephalosporins was low.

If the apparent dichotomy in antimicrobial resistance between the hospital based and community based studies is real, health facilities in the region should review their antibiotic policy to prevent misuse of antibiotics. The high antimicrobial resistance brings into focus the overuse of antibiotics in neonates with culture negative sepsis. The ANISA study showed that many neonates with negative blood cultures had viral infections.[@ref5] The low case fatality in neonates with culture negative sepsis (only one fifth of that of culture positive sepsis) in the multisite study from Delhi[@ref7] also suggests that many of these neonates either had viral infections or did not have sepsis at all. More reliable and accurate point-of-care diagnostic method(s) are needed to rule out sepsis, thereby preventing indiscriminate use of antibiotics in neonatal intensive care units.

The low antimicrobial resistance in the community allows healthcare providers in primary and even secondary level facilities to use first line antibiotics in neonates with sepsis. Steps to prevent misuse of antibiotics in other sectors such as agriculture and restriction of over-the-counter antibiotics[@ref15] [@ref16] would ensure that the antimicrobial resistance rates remain low in community settings.

Next steps
==========

Surveillance and research
-------------------------

We need reliable data to track progress on neonatal sepsis in the region to enable benchmarking and cross-learning and inform policy making. A regional surveillance database---possibly under the umbrella of the South Asian Association for Regional Cooperation---could provide such a mechanism, alongside surveillance databases within each country. This could begin with passive surveillance using uniform definitions and be followed up by active surveillance. [Box 2](#box2){ref-type="boxed-text"} lists the major research priorities in the region.

###### Research priorities for neonatal sepsis in South Asia

-   Establish a subnational/national surveillance database to evaluate and monitor the burden of neonatal sepsis, sepsis related mortality, and antimicrobial resistance

-   Implementation research---quality improvement initiatives---to scale up the coverage of known interventions

-   Identify the source of infection and transmission pathways of common pathogens

-   Evaluate the impact of introducing antimicrobial stewardship programmes at different levels of health facilities

-   Develop and validate point-of-care diagnostic method(s) for rapid and accurate diagnosis of sepsis

Quality of care and antimicrobial stewardship in hospitals
----------------------------------------------------------

Most health facilities in the region continue to be the "hot beds" of infection transmission in sick and vulnerable neonates.[@ref10] Lack of essential equipment and supplies including soap, sinks, running water, and disposables; overcrowding and understaffing; and suboptimal disinfection practices increase the risk of horizontal transmission of infections from the labour rooms or neonatal intensive care unit.[@ref10] The twofold greater risk of sepsis in hospital based studies compared with community based studies suggests that horizontal transmission---that is, healthcare associated infections---plays a major part in the high incidence of neonatal sepsis in the region. Selective referral of high risk neonates to hospitals may also account for this. With increasing rates of facility births, the burden of neonatal sepsis is bound to increase unless radical measures to improve the quality of care are implemented.

Antimicrobial stewardship programmes must be implemented to rationalise antibiotic use. Policy makers and other stakeholders should develop guidelines and toolkits to facilitate implementation of these programmes across health facilities at different levels of the health system. Steps should be simplified and continuous monitoring and auditing done to inform healthcare providers of the progress made. [Figure 1](#f1){ref-type="fig"} depicts a simplified model of antimicrobial stewardship programmes for use in health facilities in the region.[@ref12] [@ref13] [@ref14]

![Proposed model of antimicrobial stewardship programme for health facilities in South Asia. Adapted from Ramasethu 2017; Patel 2012; Cantey 2014](chas45301.f1){#f1}

Scale up effective interventions
--------------------------------

The Every Newborn series on quality of care at birth identified that scaling up of evidence based interventions could reduce infection related neonatal deaths by 84% globally.[@ref17] This is likely to have a major impact in South Asian countries[@ref3] because the existing coverage of these interventions in almost all countries is low, except in Maldives and Sri Lanka. For example, the proportion of pregnant women receiving at least four antenatal visits in Afghanistan (18%), Bangladesh (31%), India (51%), Nepal (69%), and Pakistan (37%) is low. The proportion of births attended by skilled health workers is 51%, 42%, 81%, 58%, and 55%, respectively.[@ref18] The median coverage of clean birth practices is 33.9%,[@ref3] and of the first postnatal check-up in the first two days of birth is 31% in all countries except Maldives and Sri Lanka.[@ref18] [Figure 2](#f2){ref-type="fig"} lists key interventions that could reduce the high burden of sepsis, sepsis related mortality, and antimicrobial resistance.

![Key interventions to reduce the burden of sepsis and antimicrobial resistance in South Asia. \*Indicates interventions that are more relevant to the region](chas45301.f2){#f2}

Concerted efforts at national and regional levels to identify health system related issues resulting in high incidence of sepsis and antimicrobial resistance, to improve the coverage of known interventions, and to implement context specific solutions that are simple and effective, along with a strong political will, will go a long way to reduce the burden of sepsis related mortality and morbidity in the region.

###### Key messages

-   The incidence of neonatal sepsis in South Asia is 4 to 10 times higher than that in developed countries

-   Unlike high income countries with a predominance of group B streptococci, Gram negative organisms predominate, possibly indicating horizontal transmission of infections from the environment and healthcare providers

-   About 50-88% of common isolates from the health facilities are resistant to first line antibiotics---ampicillin and gentamicin

-   Simple, evidence based interventions can help, such as better asepsis, hand hygiene, and exclusive breastfeeding and establishing antimicrobial stewardship programmes

Extra material supplied by the author

###### 

Appendix: Details of methods and included studies

See [www.bmj.com/neglected-disease-innovation](http://www.bmj.com/neglected-disease-innovation) for other articles in the series.
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